These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15388253)

  • 1. Immunogenicity of SARS inactivated vaccine in BALB/c mice.
    Xiong S; Wang YF; Zhang MY; Liu XJ; Zhang CH; Liu SS; Qian CW; Li JX; Lu JH; Wan ZY; Zheng HY; Yan XG; Meng MJ; Fan JL
    Immunol Lett; 2004 Sep; 95(2):139-43. PubMed ID: 15388253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Zhang CH; Guo ZM; Zheng HY; Lu JH; Wang YF; Yan XG; Zhao Y; DU XW; Zhang X; Fang L; Ling WH; Qi SY; Yu XB; Zhong NS
    Chin Med J (Engl); 2004 Nov; 117(11):1625-9. PubMed ID: 15569476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
    Zhang CH; Lu JH; Wang YF; Zheng HY; Xiong S; Zhang MY; Liu XJ; Li JX; Wan ZY; Yan XG; Qi SY; Cui Z; Zhang B
    Vaccine; 2005 May; 23(24):3196-201. PubMed ID: 15837220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
    Lin JT; Zhang JS; Su N; Xu JG; Wang N; Chen JT; Chen X; Liu YX; Gao H; Jia YP; Liu Y; Sun RH; Wang X; Yu DZ; Hai R; Gao Q; Ning Y; Wang HX; Li MC; Kan B; Dong GM; An Q; Wang YQ; Han J; Qin C; Yin WD; Dongs XP
    Antivir Ther; 2007; 12(7):1107-13. PubMed ID: 18018769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
    He Y; Zhou Y; Siddiqui P; Jiang S
    Biochem Biophys Res Commun; 2004 Dec; 325(2):445-52. PubMed ID: 15530413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
    Gai W; Zou W; Lei L; Luo J; Tu H; Zhang Y; Wang K; Tien P; Yan H
    Viral Immunol; 2008 Mar; 21(1):27-37. PubMed ID: 18355120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
    Tsunetsugu-Yokota Y; Ato M; Takahashi Y; Hashimoto S; Kaji T; Kuraoka M; Yamamoto K; Mitsuki YY; Yamamoto T; Oshima M; Ohnishi K; Takemori T
    Jpn J Infect Dis; 2007 May; 60(2-3):106-12. PubMed ID: 17515642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
    Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
    Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.
    Zhou J; Wang W; Zhong Q; Hou W; Yang Z; Xiao SY; Zhu R; Tang Z; Wang Y; Xian Q; Tang H; Wen L
    Vaccine; 2005 May; 23(24):3202-9. PubMed ID: 15837221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
    Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
    Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
    Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
    PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.